Linker Information
General Information of This Linker
| Linker ID |
LIN0POYBV
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
AU2023279443A1, Example A6, Linker
|
|||||
| Linker Type |
Cathepsin-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C77H106N16O32
|
|||||
| Isosmiles |
CC(C)[C@@H](C(N[C@H](C(NC1=CC=C(CO)C=C1)=O)CCCNC(N)=O)=O)NC([C@@H](NC([C@@H](NC([C@@H](CC([C@@H](NC([C@@H](NC(CCOCCOCCOCCOCCNC(CCN2C(C=CC2=O)=O)=O)=O)CC(N[C@@H](CCO3)C3=O)=O)=O)CC(N[C@H]4CCOC4=O)=O)=O)CC(N[C@@H](CCO5)C5=O)=O)=O)CC(N[C@H]6CCOC6=O)=O)=O)CC(N[C@@H](CCO7)C7=O)=O)=O
|
|||||
| InChI |
InChI=1S/C77H106N16O32/c1-41(2)65(71(110)88-45(4-3-18-80-77(78)116)67(106)81-44-7-5-42(40-94)6-8-44)92-70(109)54(39-62(102)86-50-16-26-125-76(50)115)91-69(108)53(38-61(101)85-49-15-25-124-75(49)114)90-66(105)43(35-58(98)82-46-12-22-121-72(46)111)34-55(95)51(36-59(99)83-47-13-23-122-73(47)112)89-68(107)52(37-60(100)84-48-14-24-123-74(48)113)87-57(97)17-21-117-28-30-119-32-33-120-31-29-118-27-19-79-56(96)11-20-93-63(103)9-10-64(93)104/h5-10,41,43,45-54,65,94H,3-4,11-40H2,1-2H3,(H,79,96)(H,81,106)(H,82,98)(H,83,99)(H,84,100)(H,85,101)(H,86,102)(H,87,97)(H,88,110)(H,89,107)(H,90,105)(H,91,108)(H,92,109)(H3,78,80,116)/t43-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,65-/m0/s1
|
|||||
| InChIKey |
QBVKNFHZMJWUHH-FDHDJOGESA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
1767.775
|
Polar area
|
676.52
|
||
|
Complexity
|
.
|
xlogp Value
|
-8.2971
|
|||
|
Heavy Count
|
125
|
Rot Bonds
|
55
|
|||
|
Hbond acc
|
32
|
Hbond Donor
|
16
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
aU2023279443A1 Example A6 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 100% | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
A mixed solvent of PBS and and Matrigel was used to prepare a cell suspension of 5.0x107 cells / mL. The prepared cell suspension was subcutaneously injected to the right flank region of female BALB/c-nu/nu mice at 0.1 mL per mouse. Individuals having a tumor volume within a range of 50 to 500 mm 3 were selected. test compound at a concentration of 3 mg/kg or the solvent alone was intravenously administered. the tumor volume was measured at Day 0 and Day 21.
Click to Show/Hide
|
||||
| In Vivo Model | NCI-N87 female BALB/c-nu/nu mice model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition rate (%) | > 14% | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
Cell growth inhibition test was carried out on HER2-positive human gastric cancer cell line (NCI-N87), the cells were treated with a test compound or an anti-HER2 antibody (trastuzumab) at a concentration of 100 ng/mL. The cells were cultured for 6 days, then CellTiter-Glo was added and the luminescence amount was measured.
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||